A blinded, controlled trial of objective measurement in Parkinson’s disease
Medical conditions with effective therapies are usually managed with objective measurement and therapeutic targets. Parkinson’s disease has effective therapies, but continuous objective measurement has only recently become available. This blinded, controlled study examined whether management of Park...
Gespeichert in:
Veröffentlicht in: | NPJ Parkinson's Disease 2020-11, Vol.6 (1), p.35-35, Article 35 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 35 |
---|---|
container_issue | 1 |
container_start_page | 35 |
container_title | NPJ Parkinson's Disease |
container_volume | 6 |
creator | Woodrow, Holly Horne, Malcolm K. Fernando, Chathurini V. Kotschet, Katya E. |
description | Medical conditions with effective therapies are usually managed with objective measurement and therapeutic targets. Parkinson’s disease has effective therapies, but continuous objective measurement has only recently become available. This blinded, controlled study examined whether management of Parkinson’s disease was improved when clinical assessment and therapeutic decisions were aided by objective measurement. The primary endpoint was improvement in the Movement Disorder Society-United Parkinson’s Disease Rating Scale’s (MDS-UPDRS) Total Score. In one arm, objective measurement assisted doctors to alter therapy over successive visits until objective measurement scores were in target. Patients in the other arm were conventionally assessed and therapies were changed until judged optimal. There were 75 subjects in the objective measurement arm and 79 in the arm with conventional assessment and treatment. There were statistically significant improvements in the moderate clinically meaningful range in the MDS-UPDRS Total, III, IV scales in the arm using objective measurement, but not in the conventionally treated arm. These findings show that global motor and non-motor disability is improved when management of Parkinson’s disease is assisted by objective measurement. |
doi_str_mv | 10.1038/s41531-020-00136-9 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7680151</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2469089182</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-da742b15c081dde82d187166c5ef9c904c1357ac9260193ca02c9b73606c9e3</originalsourceid><addsrcrecordid>eNp9kU9rFjEQxoMotrT9Ah4k4MWDazPJbv5chFL8BxUFvYdsMm_N625Sk92CN7-GX6-fpNG31urB0ww8v3lmhoeQR8CeAxP6uPYwCOgYZx1jIGRn7pF9LpToNBvU_Tv9Hjmqdcsa1UttBvaQ7AnBTWuHffLuhI5TTAHDM-pzWkqeJgx0KdFNNG9oHrfol3iJdEZX14IzpoXGRD-48iWmmtPV9x-VhlibjIfkwcZNFY9u6gH5-Orlp9M33dn7129PT84636t-6YJTPR9h8ExDCKh5AK1ASj_gxnjDeg9iUM4bLhkY4R3j3oxKSCa9QXFAXuxcL9ZxxuDbRcVN9qLE2ZVvNrto_1ZS_GzP86VVUjMYoBk8vTEo-euKdbFzrB6nySXMa7W8l4ZpA5o39Mk_6DavJbXnGqUEGAUgGsV3lC-51oKb22OA2Z9x2V1ctsVlf8VlTRt6fPeN25Hf4TRA7IDapHSO5c_u_9heAxkloOs</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2473197113</pqid></control><display><type>article</type><title>A blinded, controlled trial of objective measurement in Parkinson’s disease</title><source>PubMed (Medline)</source><source>SpringerOpen</source><source>DOAJ (Directory of Open Access Journals)</source><source>EZB Electronic Journals Library</source><source>Nature (Open access)</source><source>PubMed Central Open Access</source><creator>Woodrow, Holly ; Horne, Malcolm K. ; Fernando, Chathurini V. ; Kotschet, Katya E.</creator><creatorcontrib>Woodrow, Holly ; Horne, Malcolm K. ; Fernando, Chathurini V. ; Kotschet, Katya E. ; Treat to Target Study Group ; Treat to Target Study Group</creatorcontrib><description>Medical conditions with effective therapies are usually managed with objective measurement and therapeutic targets. Parkinson’s disease has effective therapies, but continuous objective measurement has only recently become available. This blinded, controlled study examined whether management of Parkinson’s disease was improved when clinical assessment and therapeutic decisions were aided by objective measurement. The primary endpoint was improvement in the Movement Disorder Society-United Parkinson’s Disease Rating Scale’s (MDS-UPDRS) Total Score. In one arm, objective measurement assisted doctors to alter therapy over successive visits until objective measurement scores were in target. Patients in the other arm were conventionally assessed and therapies were changed until judged optimal. There were 75 subjects in the objective measurement arm and 79 in the arm with conventional assessment and treatment. There were statistically significant improvements in the moderate clinically meaningful range in the MDS-UPDRS Total, III, IV scales in the arm using objective measurement, but not in the conventionally treated arm. These findings show that global motor and non-motor disability is improved when management of Parkinson’s disease is assisted by objective measurement.</description><identifier>ISSN: 2373-8057</identifier><identifier>EISSN: 2373-8057</identifier><identifier>DOI: 10.1038/s41531-020-00136-9</identifier><identifier>PMID: 33298955</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/308/409 ; 692/617/375/1718 ; Biomedical and Life Sciences ; Biomedicine ; Decision making ; Demographics ; Dyskinesia ; Neurology ; Neurosciences ; Parkinson's disease</subject><ispartof>NPJ Parkinson's Disease, 2020-11, Vol.6 (1), p.35-35, Article 35</ispartof><rights>The Author(s) 2020</rights><rights>The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-da742b15c081dde82d187166c5ef9c904c1357ac9260193ca02c9b73606c9e3</citedby><cites>FETCH-LOGICAL-c474t-da742b15c081dde82d187166c5ef9c904c1357ac9260193ca02c9b73606c9e3</cites><orcidid>0000-0001-9427-2100</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680151/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680151/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,27926,27927,41122,42191,51578,53793,53795</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33298955$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Woodrow, Holly</creatorcontrib><creatorcontrib>Horne, Malcolm K.</creatorcontrib><creatorcontrib>Fernando, Chathurini V.</creatorcontrib><creatorcontrib>Kotschet, Katya E.</creatorcontrib><creatorcontrib>Treat to Target Study Group</creatorcontrib><creatorcontrib>Treat to Target Study Group</creatorcontrib><title>A blinded, controlled trial of objective measurement in Parkinson’s disease</title><title>NPJ Parkinson's Disease</title><addtitle>npj Parkinsons Dis</addtitle><addtitle>NPJ Parkinsons Dis</addtitle><description>Medical conditions with effective therapies are usually managed with objective measurement and therapeutic targets. Parkinson’s disease has effective therapies, but continuous objective measurement has only recently become available. This blinded, controlled study examined whether management of Parkinson’s disease was improved when clinical assessment and therapeutic decisions were aided by objective measurement. The primary endpoint was improvement in the Movement Disorder Society-United Parkinson’s Disease Rating Scale’s (MDS-UPDRS) Total Score. In one arm, objective measurement assisted doctors to alter therapy over successive visits until objective measurement scores were in target. Patients in the other arm were conventionally assessed and therapies were changed until judged optimal. There were 75 subjects in the objective measurement arm and 79 in the arm with conventional assessment and treatment. There were statistically significant improvements in the moderate clinically meaningful range in the MDS-UPDRS Total, III, IV scales in the arm using objective measurement, but not in the conventionally treated arm. These findings show that global motor and non-motor disability is improved when management of Parkinson’s disease is assisted by objective measurement.</description><subject>692/308/409</subject><subject>692/617/375/1718</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Decision making</subject><subject>Demographics</subject><subject>Dyskinesia</subject><subject>Neurology</subject><subject>Neurosciences</subject><subject>Parkinson's disease</subject><issn>2373-8057</issn><issn>2373-8057</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp9kU9rFjEQxoMotrT9Ah4k4MWDazPJbv5chFL8BxUFvYdsMm_N625Sk92CN7-GX6-fpNG31urB0ww8v3lmhoeQR8CeAxP6uPYwCOgYZx1jIGRn7pF9LpToNBvU_Tv9Hjmqdcsa1UttBvaQ7AnBTWuHffLuhI5TTAHDM-pzWkqeJgx0KdFNNG9oHrfol3iJdEZX14IzpoXGRD-48iWmmtPV9x-VhlibjIfkwcZNFY9u6gH5-Orlp9M33dn7129PT84636t-6YJTPR9h8ExDCKh5AK1ASj_gxnjDeg9iUM4bLhkY4R3j3oxKSCa9QXFAXuxcL9ZxxuDbRcVN9qLE2ZVvNrto_1ZS_GzP86VVUjMYoBk8vTEo-euKdbFzrB6nySXMa7W8l4ZpA5o39Mk_6DavJbXnGqUEGAUgGsV3lC-51oKb22OA2Z9x2V1ctsVlf8VlTRt6fPeN25Hf4TRA7IDapHSO5c_u_9heAxkloOs</recordid><startdate>20201120</startdate><enddate>20201120</enddate><creator>Woodrow, Holly</creator><creator>Horne, Malcolm K.</creator><creator>Fernando, Chathurini V.</creator><creator>Kotschet, Katya E.</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9427-2100</orcidid></search><sort><creationdate>20201120</creationdate><title>A blinded, controlled trial of objective measurement in Parkinson’s disease</title><author>Woodrow, Holly ; Horne, Malcolm K. ; Fernando, Chathurini V. ; Kotschet, Katya E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-da742b15c081dde82d187166c5ef9c904c1357ac9260193ca02c9b73606c9e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>692/308/409</topic><topic>692/617/375/1718</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Decision making</topic><topic>Demographics</topic><topic>Dyskinesia</topic><topic>Neurology</topic><topic>Neurosciences</topic><topic>Parkinson's disease</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Woodrow, Holly</creatorcontrib><creatorcontrib>Horne, Malcolm K.</creatorcontrib><creatorcontrib>Fernando, Chathurini V.</creatorcontrib><creatorcontrib>Kotschet, Katya E.</creatorcontrib><creatorcontrib>Treat to Target Study Group</creatorcontrib><creatorcontrib>Treat to Target Study Group</creatorcontrib><collection>SpringerOpen</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>NPJ Parkinson's Disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Woodrow, Holly</au><au>Horne, Malcolm K.</au><au>Fernando, Chathurini V.</au><au>Kotschet, Katya E.</au><aucorp>Treat to Target Study Group</aucorp><aucorp>Treat to Target Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A blinded, controlled trial of objective measurement in Parkinson’s disease</atitle><jtitle>NPJ Parkinson's Disease</jtitle><stitle>npj Parkinsons Dis</stitle><addtitle>NPJ Parkinsons Dis</addtitle><date>2020-11-20</date><risdate>2020</risdate><volume>6</volume><issue>1</issue><spage>35</spage><epage>35</epage><pages>35-35</pages><artnum>35</artnum><issn>2373-8057</issn><eissn>2373-8057</eissn><abstract>Medical conditions with effective therapies are usually managed with objective measurement and therapeutic targets. Parkinson’s disease has effective therapies, but continuous objective measurement has only recently become available. This blinded, controlled study examined whether management of Parkinson’s disease was improved when clinical assessment and therapeutic decisions were aided by objective measurement. The primary endpoint was improvement in the Movement Disorder Society-United Parkinson’s Disease Rating Scale’s (MDS-UPDRS) Total Score. In one arm, objective measurement assisted doctors to alter therapy over successive visits until objective measurement scores were in target. Patients in the other arm were conventionally assessed and therapies were changed until judged optimal. There were 75 subjects in the objective measurement arm and 79 in the arm with conventional assessment and treatment. There were statistically significant improvements in the moderate clinically meaningful range in the MDS-UPDRS Total, III, IV scales in the arm using objective measurement, but not in the conventionally treated arm. These findings show that global motor and non-motor disability is improved when management of Parkinson’s disease is assisted by objective measurement.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>33298955</pmid><doi>10.1038/s41531-020-00136-9</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-9427-2100</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2373-8057 |
ispartof | NPJ Parkinson's Disease, 2020-11, Vol.6 (1), p.35-35, Article 35 |
issn | 2373-8057 2373-8057 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7680151 |
source | PubMed (Medline); SpringerOpen; DOAJ (Directory of Open Access Journals); EZB Electronic Journals Library; Nature (Open access); PubMed Central Open Access |
subjects | 692/308/409 692/617/375/1718 Biomedical and Life Sciences Biomedicine Decision making Demographics Dyskinesia Neurology Neurosciences Parkinson's disease |
title | A blinded, controlled trial of objective measurement in Parkinson’s disease |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T15%3A59%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20blinded,%20controlled%20trial%20of%20objective%20measurement%20in%20Parkinson%E2%80%99s%20disease&rft.jtitle=NPJ%20Parkinson's%20Disease&rft.au=Woodrow,%20Holly&rft.aucorp=Treat%20to%20Target%20Study%20Group&rft.date=2020-11-20&rft.volume=6&rft.issue=1&rft.spage=35&rft.epage=35&rft.pages=35-35&rft.artnum=35&rft.issn=2373-8057&rft.eissn=2373-8057&rft_id=info:doi/10.1038/s41531-020-00136-9&rft_dat=%3Cproquest_pubme%3E2469089182%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2473197113&rft_id=info:pmid/33298955&rfr_iscdi=true |